Table 2 |
|||||
|
The relative AMI risk associated with the use individual NSAIDs compared with remote or no use. |
|||||
|
Drug [ref.] |
Relative AMI risk |
95% CI |
Test for heterogeneity |
Test for inconsistency |
|
|
|
|||||
|
χ2 |
P value |
I2 |
|||
|
|
|||||
|
Diclofenac |
1.41 |
1.20–1.65 |
9.79 |
0.08 |
48.9% |
|
[27] |
1.38 |
1.08–1.77 |
|||
|
[16] |
1.68 |
1.14–2.48 |
|||
|
[19] |
1.18 |
0.99–1.40 |
|||
|
[6] |
1.55 |
1.39–1.72 |
|||
|
[18] |
1.23 |
1.00–1.51 |
|||
|
Ibuprofen |
1.11 |
1.04–1.18 |
8.26 |
0.41 |
3.2% |
|
[25] |
1.15 |
1.03–1.29 |
|||
|
[24] |
1.01 |
0.77–1.33 |
|||
|
[27] |
1.17 |
0.87–1.58 |
|||
|
[28] |
1.02 |
0.88–1.18 |
|||
|
[16] |
0.74 |
0.35–1.56 |
|||
|
[19] |
1.06 |
0.87–1.29 |
|||
|
[20] |
1.06 |
0.96–1.17 |
|||
|
[6] |
1.24 |
1.11–1.39 |
|||
|
[18] |
1.16 |
0.92–1.46 |
|||
|
Naproxen |
0.99 |
0.88–1.12 |
23.91 |
0.01 |
54% |
|
[25] |
0.95 |
0.82–1.10 |
|||
|
[24] |
0.93 |
0.74–1.17 |
|||
|
[27] |
0.68 |
0.41–1.12 |
|||
|
[28] |
0.84 |
0.72–0.98 |
|||
|
[16] |
0.57 |
0.31–1.05 |
|||
|
[23] |
1.00 |
0.59–1.68 |
|||
|
[19] |
0.89 |
0.64–1.24 |
|||
|
[20] |
1.14 |
1.00–1.30 |
|||
|
[6] |
1.27 |
1.01–1.60 |
|||
|
[21] |
1.50 |
0.99–2.28 |
|||
|
[22] |
1.17 |
0.75–1.83 |
|||
|
[18] |
0.96 |
0.66–1.39 |
|||
|
|
|||||
|
AMI, acute myocardial infarction; CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug. |
|||||
|
Singh et al. Arthritis Research & Therapy 2006 8:R153 doi:10.1186/ar2047 |
|||||